There are plenty of reasons why many investors enjoy holding shares in Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare businesses. With the company's impressive track record of dividend payments and its pipeline's massive throughput of new medicines, it's clear that this stock will be around for the foreseeable future.

But even if it's a stalwart for many portfolios, it isn't perfect. Let's examine two major reasons that make the stock worth purchasing, and two reasons that might make it better to sell or avoid.

Johnson & Johnson's product mix makes it worth buying in times like now when inflation is higher than average. Some of its core offerings are branded consumer health goods like Tylenol and Band-Aids, for which there's well-established and highly durable demand. Even when the economy is showing signs of struggling mightily, as during the fourth quarter of 2022, its consumer health segment still grew by 1% on a reported basis, reaching more than $3.7 billion.

Continue reading

Source Fool.com